Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Essential Drug Prices Less Severe Than Expected; Some Prices See Increases

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's National Development and Reform Commission issued Oct. 2 a guideline price for its Essential Drug List, which stipulates price ceilings for 296 drugs on the first part of the list

You may also be interested in...



Dance With Domestic Companies: Pfizer And Merck Look To Broaden Market Access In China Via JVs

Merck/Simcere, Pfizer/Hisun launched JVs in China this week to increase sales in outlying cities.

Dance With Domestic Companies: Pfizer And Merck Look To Broaden Market Access In China Via JVs

Merck/Simcere, Pfizer/Hisun launched JVs in China this week to increase sales in outlying cities.

Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal

NANJING, China - A few weeks after Merck & Co.'s China affiliate MSD and one of China's leading drug makers Simcere Pharmaceutical Group announced a new joint venture to expand access to critical lifestyle drugs across China, the two companies unveiled more details to their innovative partnership

Related Content

UsernamePublicRestriction

Register

LL043097

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel